To investigate the safety of Stemchymal® via intravenous (IV) infusion in acute liver failure (ALF) and acute on chronic liver failure (ACLF) patients.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
ALF/ ACLF patients will receive Stemchymal® through intravenous infusion
Taipei Veterans General Hospital
Taipei, Taiwan
The incidence of adverse events (AEs) and suspected unexpected serious adverse reaction (SUSAR)
Time frame: 12 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.